@article{article_648445, title={Imatinib Mesylate Treatment in Chronic Myeloid Leukemia}, journal={Sakarya Tıp Dergisi}, volume={10}, pages={107–112}, year={2020}, DOI={10.31832/smj.648445}, author={Çekdemir, Demet and Gunduz, Mehmet}, keywords={Kronik miyeloid lösemi,tedavi,imatinib mesilat}, abstract={<p style="margin-top:0cm;margin-right:0cm;margin-bottom:6pt;margin-left:0cm;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us">Objective: </span> </b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us"> </span> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us">To evaluate retrospectively the efficacy of treatment
in chronic myeloid leukemia (CML) patients followed up in our center and
receiving imatinib treatment. </span> <span style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;"> </span> </p> <p> </p> <p style="margin-top:0cm;margin-right:0cm;margin-bottom:6pt;margin-left:0cm;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us">Materials and </span> </b> <b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us">Methods: </span> </b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us">Eighty-five chronic phase CML patients with adequate
clinical and laboratory data were included in the study. These patients had not
given hematological or cytogenetic responses after interferon treatment, or had
intolerance to IFN treatment or received imatinib treatment as a first-line
treatment in late and early chronic stage patients. </span> <span style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;"> </span> </p> <p> </p> <p style="margin-top:0cm;margin-right:0cm;margin-bottom:6pt;margin-left:0cm;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us">Results: </span> </b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us"> Forty-eight (56.5%)
patients were male and 37 (43.5%) of them were female. The median age at
diagnosis was 52 years (19-79). The mean follow-up period was 45 (12-158)
months. In the follow-up, 6 of the chronic phase patients progressed to blastic
and accelerated phase. In the third month of imatinib treatment, 77 (90.6%)
patients had complete hematologic response and 85 (100%) patients had full
hematologic response at 18 months. In our study, cytogenetic data of 78
patients with adequate metaphase (≥ 20) could be evaluated within the first 18
months after the diagnosis was made. At the end of 18 months, 68 (87.2%) of 78
patients had complete cytogenetic response. </span> <span style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;"> </span> </p> <p> </p> <p> </p> <p style="margin-top:0cm;margin-right:0cm;margin-bottom:6pt;margin-left:0cm;text-align:justify;line-height:200%;"> <b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us">Conclusion: </span> </b> <span lang="en-us" style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;" xml:lang="en-us"> Imatinib is well tolerated by CML patients and is a
superior treatment alternative to other therapies other than bone marrow
transplantation in achieving hematological and cytogenetic response. </span> <span style="font-size:10pt;line-height:200%;font-family:Arial, sans-serif;"> </span> </p> <p> </p>}, number={1}, publisher={Sakarya Üniversitesi}